Vertex Pharmaceuticals Inc. has earned a $15 million milestone payment from a drug development partner thanks to the company's recent progress on a new treatment for hepatitis C. The Cambridge, Mass. company (Nasdaq: VRTX) announced on Wednesday that development partner Janssen Pharmaceutica NV made the payment due to encouraging safety results generated by an ongoing mid-stage human clinical trial of telaprevir (VX-950).
